Alison M. Weppler

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 215 citations

Medicine, Oncology, Pharmacotherapy +16

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Rafaela Kramer, Anne Zaremba, Alvaro Moreira et al. · European Journal of Cancer · 2021 · 94 citations

Medicine, Hematology, Oncology +14

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren Brown, Alison M. Weppler, Prachi Bhave et al. · Journal for ImmunoTherapy of Cancer · 2021 · 90 citations · Full text

Life Sciences, Immunology, Oncology +17

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

Jenny Lee, Alexander M. Menzies, Matteo S. Carlino et al. · Clinical Cancer Research · 2020 · 82 citations · Full text

Medicine, Clinical Sciences, Oncology +17

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani, Medhat Osman, Alison M. Weppler et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 70 citations

Medicine, Nuclear Medicine, Oncology +17